| Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease VKM Halagappa, Z Guo, M Pearson, Y Matsuoka, RG Cutler, FM LaFerla, ... Neurobiology of disease 26 (1), 212-220, 2007 | 632 | 2007 |
| Cdk5 is a key factor in tau aggregation and tangle formation in vivo W Noble, V Olm, K Takata, E Casey, O Mary, J Meyerson, K Gaynor, ... Neuron 38 (4), 555-565, 2003 | 581 | 2003 |
| Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid Y Matsuoka, M Saito, J LaFrancois, M Saito, K Gaynor, V Olm, L Wang, ... Journal of Neuroscience 23 (1), 29-33, 2003 | 413 | 2003 |
| Adducin: structure, function and regulation Y Matsuoka*, X Li, V Bennett Cellular and Molecular Life Sciences CMLS 57, 884-895, 2000 | 404 | 2000 |
| Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer’s disease Y Matsuoka, M Picciano, B Malester, J LaFrancois, C Zehr, ... The American journal of pathology 158 (4), 1345-1354, 2001 | 374 | 2001 |
| Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter Y Matsuoka, M Vila, S Lincoln, A McCormack, M Picciano, J LaFrancois, ... Neurobiology of disease 8 (3), 535-539, 2001 | 357 | 2001 |
| Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease Y Kitamura, S Shimohama, W Kamoshima, T Ota, Y Matsuoka, Y Nomura, ... Brain research 780 (2), 260-269, 1998 | 305 | 1998 |
| Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model C Hirata-Fukae, HF Li, HS Hoe, AJ Gray, SS Minami, K Hamada, T Niikura, ... Brain research 1216, 92-103, 2008 | 295 | 2008 |
| Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-γ in Alzheimer's disease brains Y Kitamura, S Shimohama, H Koike, J Kakimura, Y Matsuoka, Y Nomura, ... Biochemical and biophysical research communications 254 (3), 582-586, 1999 | 280 | 1999 |
| Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury DJ Loane, A Pocivavsek, CEH Moussa, R Thompson, Y Matsuoka, ... Nature medicine 15 (4), 377-379, 2009 | 271 | 2009 |
| A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease Y Matsuoka, Y Jouroukhin, AJ Gray, L Ma, C Hirata-Fukae, HF Li, L Feng, ... Journal of Pharmacology and Experimental Therapeutics 325 (1), 146-153, 2008 | 263 | 2008 |
| Presenilin redistribution associated with aberrant cholesterol transport enhances β-amyloid production in vivo M Burns, K Gaynor, V Olm, M Mercken, J LaFrancois, L Wang, ... Journal of Neuroscience 23 (13), 5645-5649, 2003 | 224 | 2003 |
| Biological significance of isoaspartate and its repair system T Shimizu, Y Matsuoka, T Shirasawa Biological and Pharmaceutical Bulletin 28 (9), 1590-1596, 2005 | 223 | 2005 |
| Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells Y Kitamura, T Kosaka, JI Kakimura, Y Matsuoka, Y Kohno, Y Nomura, ... Molecular pharmacology 54 (6), 1046-1054, 1998 | 221 | 1998 |
| Changes of p53 in the brains of patients with Alzheimer's disease Y Kitamura, S Shimohama, W Kamoshima, Y Matsuoka, Y Nomura, ... Biochemical and biophysical research communications 232 (2), 418-421, 1997 | 216 | 1997 |
| DAB1 and Reelin effects on amyloid precursor protein and ApoE receptor 2 trafficking and processing HS Hoe, TS Tran, Y Matsuoka, BW Howell, GW Rebeck Journal of Biological Chemistry 281 (46), 35176-35185, 2006 | 202 | 2006 |
| Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice RL Nelson, Z Guo, VM Halagappa, M Pearson, AJ Gray, Y Matsuoka, ... Experimental neurology 205 (1), 166-176, 2007 | 200 | 2007 |
| Fibrillar β-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer’s disease Y Matsuoka, M Picciano, J La Francois, K Duff Neuroscience 104 (3), 609-613, 2001 | 191 | 2001 |
| Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage Y Matsuoka, AJ Gray, C Hirata-Fukae, SS Minami, EG Waterhouse, ... Journal of molecular neuroscience 31, 165-170, 2007 | 185 | 2007 |
| Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice CA Lemere, ET Spooner, J LaFrancois, B Malester, C Mori, JF Leverone, ... Neurobiology of disease 14 (1), 10-18, 2003 | 180 | 2003 |
